| 18th Decembre 2019 | Announcement : Neuro-Sys and Sciomics announce a collaboration to co-develop an unrivaled integrated preclinical solution in neurodegenerative disorders. More information in the joint press-release .
| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.
| June 2018 | Complement component 5a receptor 2 (C5AR2) deficient mice are protected from inflammation and fibrosis in response to ischemia reperfusion injury. Our scioPhospho platform supported scientists at the Medical School Hannover to elucidate the underlying mechanism. The data were recently published in Kidney International.
| January 2018 | A scioDiscover protein microarray study contributed to an article in Cell Reports. In this study Gerard Ruiz-Babot et al. analysed a donor specific reprogramming of cells.
Customer testimonial Leonardo Guasti, PhD (senior author):
This has undoubtedly opened new avenues in our research. We have found the Sciomics team to be extremely helpful and efficient during the whole process, from advising the best strategy to the final interpretation of results.
| January 2018 | Article on the StartUp Sciomics and our antibody microarray platform by our partner SCHOTT nexterion.
Great news @aacr ! Good news for all people in home office ! https://t.co/QM6xKhGi4M
Immune response profiling in #COVID19: A parallel analysis of 121 #cytokines and 141 cell surface markers… https://t.co/K7FvwhF4iD
RT @car_endo: Finally, let's look at the incidence of #endometrial #cancer in #Germany! With more than 10,000 new cases each year, #endomet…
All of our protein profiling and biomarker discovery capabilities remain fully operational. Clearly, #COVID19 res… https://t.co/xlNc6zgwy7
RT @car_endo: Endometrial cancer (EC) is the most common gynaecological cancer in the more economically developed countries and the 6th mos…